The sparse fur mouse as a model for gene therapy in ornithine carbamoyltransferase deficiency

The sparse fur (spf/Y) mouse was valuated as a model for studying gene therapy in ornithine carbamoyltransferase transferase deficiency (OCTD), the most common inborn error of urea synthesis. Previous studies have defined a number of biochemical characteristics of this animal model that are analogous to the human disease: OCTD in liver, elevated ammonium and glutamine, low citrulline and arginine in plasma, elevated urinary erotic acid excretion, neurochemical alterations and responsiveness to alternative pathway therapy. in this study, metabolic flux, survival, behavior and learning of these animals were examined in preparation for a trial of gene therapy. We found that as has been previously reported, OCT activity in liver ranged from 10 to 20% of control. Yet, stable isotope studies using N-15 ammonium chloride to follow ureagenesis in vivo showed 55% of normal urea synthetic capacity. This suggests that partial correction with gene therapy may be sufficient to normalize urea synthesis. Although it has been suggested that liver OCTD and its consequent metabolic effects normalize without treatment by adulthood in the spf/Y mouse, we did not find this to be the case. We documented that the spf/Y mouse had a markedly decreased lifespan (<10% of normal) and remained runted throughout life. In terms of behavior, the spf/Y mice had evidence of decreased learning in a passive avoidance task that was not attributable to alterations in activity. These clearly definable metabolic and behavioral abnormalities suggest that the spf/Y mouse should prove a useful model for studying the efficacy of gene therapy in OCTD.